Rottenstein Law Group Publicizing New Research Showing Some SSRIs Increase Heart Arrhythmia Risk

Share Article

The Rottenstein Law Group, which represents clients with injuries allegedly caused by antidepressants and has compiled a list of drugs that fall into the selective serotonin reuptake inhibitor (SSRI) category of antidepressants, is publicizing new research showing that some SSRIs have been linked to increased risk of serious heart arrhythmia.

Past News Releases

The Rottenstein Law Group, which represents clients with injuries allegedly caused by antidepressants and has compiled a list of drugs that fall into the selective serotonin reuptake inhibitor (SSRI) category of antidepressants, is publicizing new research showing that some SSRIs have been linked to increased risk of serious heart arrhythmia.

According to the web site RedOrbit.com*, the British Medical Journal on Jan 29, 2013, published a study showing that Citalopram (brand name: Celexa) and escitalopram (brand name: Lexapro) “trigger a disturbance in QT interval (the duration of electrical activity of the heart muscle) heart rhythms.” Lead study author Dr. Roy Perlis and his colleagues “confirmed through analysis a slight but significant QT prolongation with higher doses of citalopram,” RedOrbit.com reports. “Although some QT variation is normal, a longer interval can upset timing of the heartbeat and lead to dizziness, fainting, and depending on severity, sudden death.”

In a statement, Dr. Perlis said, “The impetus for this study came directly from the phone calls we received from colleagues and from patients taking citalopram asking what they should do.”

About THE ROTTENSTEIN LAW GROUP
The Rottenstein Law Group is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)